Kyowa Kirin Co. Ltd.

4151

JP3256000005

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 11:30:00 31/05/2024 am IST			5-day change	1st Jan Change
2,656 ^JPY	+2.87%		+2.53%	+12.05%

07/05	Kyowa Kirin's Profit Up 15% in Q1	MT
06/05	Kyowa Kirin Buys Back Shares for 5.6 Billion Yen in April	MT

Komeri Co.,Ltd. Provides Consolidated Earnings Guidance for the Year Ending Dec. 31, 2020

October 30, 2020 at 12:00 pm IST

Komeri Co.,Ltd. provided consolidated earnings guidance for the year ending Dec. 31, 2020. The company expects, operating revenue of JPY 313,000 million, core operating of JPY 60,000 million, profit before tax of JPY 53,000 million, profit of JPY 44,000 million or JPY 81.92 per basic share.

Latest news about Kyowa Kirin Co. Ltd.

Kyowa Kirin's Profit Up 15% in Q1	07/05	MT
Kyowa Kirin Buys Back Shares for 5.6 Billion Yen in April	06/05	MT
BridgeBio Pharma Shares Decline After Q1 Financial Results	02/05	MT
U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease	08/04	RE
Kyowa Kirin Buys Back 4 Billion Yen Worth of Shares in March	03/04	MT
Tranche Update on Kyowa Kirin Co., Ltd.'s Equity Buyback Plan announced on February 7, 2024.	02/04	CI
Japanese Shares Slip into Red Amid Profit-Taking; Tokyo Inflation Eyed	25/03	MT
Kyowa Kirin to Allocate Over 84,000 Treasury Shares as Director, Officer Compensation	25/03	MT
Kyowa Kirin's gene therapy most expensive US drug with $4.3 million price tag	20/03	RE
US approves first gene therapy for children with rare genetic disease	19/03	RE
US approves first gene therapy for rare genetic disease	18/03	RE
Kyowa Kirin Co., Ltd. to Present Phase 2B Post-Hoc Analysis and Symposium At the American Academy of Dermatology Annual Meeting 2024	08/03	CI
Kyowa Kirin Buys Back Nearly 3 Billion Yen of Shares	05/03	MT
China Deflation, Bank of Japan Roil Asian Stock Markets	08/02	MT
Japan's Nikkei closes at 34-year peak on dovish BOJ; tech shares soar	08/02	RE
Japan's Nikkei leaps to 2-week high on tech stocks, yen boost	08/02	RE
BridgeBio Pharma Unit to Grant Kyowa Kirin License for Infigratinib in Japan	07/02	MT
Kyowa Kirin's Profit Up 52% in Fiscal 2023	07/02	MT
Kyowa Kirin Co., Ltd. Provides Dividend Guidance for the Year Ending December 31, 2024	07/02	CI
Kyowa Kirin Co., Ltd. Declares Dividend for the Fiscal Year Ended December 31, 2023, Payable on March 25, 2024; Provides Dividend Guidance for the Second Quarter of 2024	07/02	CI
Kyowa Kirin Co., Ltd. Provides Consolidated Earnings Guidance for the Full Year Ending December 31, 2024	07/02	CI
Kyowa Kirin Co., Ltd. announces an Equity Buyback for 17,000,000 shares, representing 3.16% for KRW 40,000 million.	07/02	CI
Kyowa Hakko Kirin Co., Ltd. authorizes a Buyback Plan.	07/02	CI
Kyowa Kirin Announces First Patient Enrolled in the Phase 2 Clinical Trial Evaluating Tivozanib Eye Drops in Patients with Diabetic Macular Edema	06/02	CI
Japanese Shares Skid as Inflation Slows Faster-than-Expected in January	26/01	MT

Chart Kyowa Kirin Co. Ltd.

Duration

Period

More charts

Company Profile

Kyowa Kirin Co., Ltd. specializes in the development, manufacturing and marketing of pharmaceutical and biochemical products. Net sales break down by source of revenue as follows: - sales of pharmaceutical products (92.6%): prescription products for anemia, cancers, immune and nephrology diseases treatment; - sales of licenses (7.4%). At the end of 2021, the group had 3 production sites located in Japan (2) and China. Net sales break down geographically as follows: Japan (60.9%), Asia (9%), Americas (16.3%) and Europe (13.8%).

Sector

Pharmaceuticals

Calendar

27/06/2024 - Ex-dividend day for dividende intermédiaire

Related indices

Nikkei 225

More about the company

Income Statement Evolution

More financial data

Ratings for Kyowa Kirin Co. Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2,656 JPY

Average target price

3,054 JPY

Spread / Average Target

+15.01%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
KYOWA KIRIN CO. LTD.	+12.05%	8.78B
MERCK KGAA	+15.54%	77.63B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+58.17%	4.93B
SK BIOPHARMACEUTICALS CO., LTD.	-14.94%	4.79B
YUHAN CORPORATION	0.00%	3.8B
INDIVIOR PLC	+21.94%	2.46B
BETTA PHARMACEUTICALS CO., LTD.	-26.63%	2.2B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+16.75%	2.1B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-37.97%	1.96B
VELOXIS PHARMACEUTICALS A/S	-0.50%	1.64B

Specialty & Advanced Pharmaceuticals

Kyowa Kirin Co. Ltd.

Equities

4151

JP3256000005

Pharmaceuticals

Komeri Co.,Ltd. Provides Consolidated Earnings Guidance for the Year Ending Dec. 31, 2020

EPS Revisions